

Datasheet for ABIN7596445

Sclerostin Protein (SOST) (AA 24-211) (His tag)



Overview

| Overview | |
|-------------------------------|-----------------------------------------------------------------------------------------|
| Quantity: | 250 μg |
| Target: | Sclerostin (SOST) |
| Protein Characteristics: | AA 24-211 |
| Origin: | Mouse |
| Source: | HEK-293 Cells |
| Protein Type: | Recombinant |
| Purification tag / Conjugate: | This Sclerostin protein is labelled with His tag. |
| Application: | SDS-PAGE (SDS) |
| Product Details | |
| Sequence: | QGWQAFRNDA TEVIPGLGEY PEPPPENNQT MNRAENGGRP PHHPYDAKDV SEYSCRELHY |
| | TRFLTDGPCR SAKPVTELVC SGQCGPARLL PNAIGRVKWW RPNGPDFRCI PDRYRAQRVQ |
| | LLCPGGAAPR SRKVRLVASC KCKRLTRFHN QSELKDFGPE TARPQKGRKP RPGARGAKAN |
| | QAELENAY |
| Purity: | > 90% by SDS - PAGE |
| Endotoxin Level: | < 1 EU per 1ug of protein (determined by LAL method) |
| Target Details | |
| Target: | Sclerostin (SOST) |
| Alternative Name: | SOST/Sclerostin (SOST Products) |
| Background: | SOST, also known as Sclerostin, is a member of the cerberus/DAN family. This protein is |

produced primarily by the osteocyte but is also expressed in other tissues, and has antianabolic effects on bone formation. It was originally believed to be a nonclassical bone morphogenetic protein (BMP) antagonist. More recently, sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signaling pathway. The inhibition of the Wnt pathway leads to decreased bone formation. Although the underlying mechanisms are unclear, it is believed that the antagonism of BMP-induced bone formation by sclerostin is mediated by Wnt signaling, but not BMP signaling pathways. Mutations in the gene that encodes the sclerostin protein are associated with disorders associated with high bone mass, sclerosteosis and van Buchem disease. Recombinant mouse SOST/Sclerostin, fused to His-tag at C-terminus, was expressed in HEK293 cell and purified by using conventional chromatography techniques.

Molecular Weight:

21.9kDa (194aa)

NCBI Accession:

NP_077769

Application Details

Application Notes:

Optimal working dilution should be determined by the investigator.

Restrictions:

For Research Use only

Handling

| Format: | Liquid |
|------------------|--------------------------------------------------------------------------------------------------|
| Concentration: | 0.25 mg/mL |
| Storage: | 4 °C,-20 °C,-80 °C |
| Storage Comment: | Can be stored at +2°C to +8°C for 1 week. For long term storage, aliquot and store at -20°C to - |

80°C. Avoid repeated freezing and thawing cycles.